VistaGen Therapeutics Stock Forecast, Price & News

VistaGen Therapeutics (NASDAQ:VTGN) Frequently Asked Questions

Is VistaGen Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VistaGen Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VistaGen Therapeutics stock.
View analyst ratings for VistaGen Therapeutics or view top-rated stocks.

How has VistaGen Therapeutics' stock price been impacted by COVID-19?

VistaGen Therapeutics' stock was trading at $0.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VTGN shares have increased by 260.0% and is now trading at $1.80.
View which stocks have been most impacted by COVID-19.

When is VistaGen Therapeutics' next earnings date?

VistaGen Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for VistaGen Therapeutics.

How were VistaGen Therapeutics' earnings last quarter?

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.02. VistaGen Therapeutics had a negative net margin of 2,183.17% and a negative trailing twelve-month return on equity of 36.41%. During the same quarter in the prior year, the business posted ($0.05) earnings per share.
View VistaGen Therapeutics' earnings history.

What price target have analysts set for VTGN?

3 equities research analysts have issued twelve-month price targets for VistaGen Therapeutics' shares. Their forecasts range from $5.00 to $9.00. On average, they anticipate VistaGen Therapeutics' share price to reach $6.67 in the next year. This suggests a possible upside of 270.4% from the stock's current price.
View analysts' price targets for VistaGen Therapeutics or view top-rated stocks among Wall Street analysts.

Who are VistaGen Therapeutics' key executives?

VistaGen Therapeutics' management team includes the following people:

• Shawn K. Singh, Chief Executive Officer & Director
• H. Ralph Snodgrass, President & Chief Scientific Officer (LinkedIn Profile)
• Jerrold D. Dotson, Chief Financial Officer, Secretary & VP
• Mark A. Smith, Chief Medical Officer
• Ellis Wilson, Vice President-Global Clinical Operations

Who are some of VistaGen Therapeutics' key competitors?

Some companies that are related to VistaGen Therapeutics include Madrigal Pharmaceuticals (MDGL), Amarin (AMRN), MorphoSys (MOR), Xenon Pharmaceuticals (XENE), COMPASS Pathways (CMPS), FibroGen (FGEN), Keros Therapeutics (KROS), uniQure (QURE), Nurix Therapeutics (NRIX), Rani Therapeutics (RANI), Amneal Pharmaceuticals (AMRX), Axsome Therapeutics (AXSM), ALX Oncology (ALXO), Organogenesis (ORGO) and Endo International (ENDP).
View all of VTGN's competitors.

What other stocks do shareholders of VistaGen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VistaGen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Advaxis (ADXS), Matinas BioPharma (MTNB), Rite Aid (RAD), Sorrento Therapeutics (SRNE), Lithium Americas (LAC), ImmunoGen (IMGN), Yamana Gold (AUY) and CRISPR Therapeutics (CRSP).

What is VistaGen Therapeutics' stock symbol?

VistaGen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."

Who are VistaGen Therapeutics' major shareholders?

VistaGen Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.09%), Franklin Resources Inc. (5.25%), Commodore Capital LP (2.66%), Sphera Funds Management LTD. (1.98%), Geode Capital Management LLC (1.60%) and Goldman Sachs Group Inc. (0.84%). Company insiders that own VistaGen Therapeutics stock include H Ralph Snodgrass and Jerrold Duane Dotson.
View institutional ownership trends for VistaGen Therapeutics.

Which major investors are selling VistaGen Therapeutics stock?

VTGN stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Schonfeld Strategic Advisors LLC, California State Teachers Retirement System, Morgan Stanley, Cubist Systematic Strategies LLC, Two Sigma Investments LP, Deutsche Bank AG, and New York State Common Retirement Fund.
View insider buying and selling activity for VistaGen Therapeutics or view top insider-selling stocks.

Which major investors are buying VistaGen Therapeutics stock?

VTGN stock was acquired by a variety of institutional investors in the last quarter, including Commodore Capital LP, Goldman Sachs Group Inc., EAM Global Investors LLC, Two Sigma Advisers LP, EAM Investors LLC, Victory Capital Management Inc., Millennium Management LLC, and Rafferty Asset Management LLC.
View insider buying and selling activity for VistaGen Therapeutics or or view top insider-buying stocks.

How do I buy shares of VistaGen Therapeutics?

Shares of VTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VistaGen Therapeutics' stock price today?

One share of VTGN stock can currently be purchased for approximately $1.80.

How much money does VistaGen Therapeutics make?

VistaGen Therapeutics has a market capitalization of $359.46 million and generates $1.09 million in revenue each year. The company earns $-17.93 million in net income (profit) each year or ($0.38) on an earnings per share basis.

How many employees does VistaGen Therapeutics have?

VistaGen Therapeutics employs 21 workers across the globe.

What is VistaGen Therapeutics' official website?

The official website for VistaGen Therapeutics is www.vistagen.com.

Where are VistaGen Therapeutics' headquarters?

VistaGen Therapeutics is headquartered at 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080.

How can I contact VistaGen Therapeutics?

VistaGen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 577-3600, via email at [email protected], or via fax at 888-482-2602.